Alkem Laboratories Limited (ALKEM.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹5,078.00 (+0.95%) as of
Key statistics
- Market cap
- 607.15B
- P/E (TTM)
- 28.14
- Forward P/E
- 22.69
- EPS (TTM)
- 180.44
- Dividend yield
- 0.40%
- 52-week range
- 4,811.00 – 5,933.50
- Beta
- 0.29
- Revenue (TTM)
- 150.81B
- Profit margin
- 14.31%
- Analyst target
- ₹6,002.55
- Volume
- 166.27k
About Alkem Laboratories Limited
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology, central nervous system, anti-diabetic, iron deficiency, pain management, and urology, as well as vitamins, minerals, and nutrients. It also provides cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. Alkem Laboratories Limited was incorporated in 1973 and is based in Mumbai, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Mumbai, India
- Employees
- 19,346
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.